Injectable implants have a long medical history outside of urology in areas such as aesthetic dermatology, gastroesophageal reflux, as well as for patients with glottis insufficiency. Since urethral bulking agents (UBA) were first introduced, many have come and gone and it is clear from the literature that not one has, as yet, lived up to the expectations and requirements of an ideal UBA. As a result, their place within the treatment armament for women suffering from stress urinary incontinence (SUI), is largely relegated to a last resort treatment. However, in recent years UBA treatment for female urinary incontinence has become increasingly popular due to the minimally invasive nature, safety profile and improvement in performance, also leading to a demand for a new type of urethral injectable product with additional beneficial characteristics such as full bioresorbability.
Urolon™ is here to revolutionize this segment by introducing a unique, injectable and bioresorbable urethral implant.(SUI); a pivotal trial.
Urolon™ is a Bioresorbable Urethral Implant for the treatment of stress urinary incontinence (SUI) and inherently different from traditional urethral bulking agents due to its unique performance, mode of action and bioresorption profile. It is a minimally invasive treatment using non-permanent materials that is very suitable as a first-choice treatment option before using permanent injectables or surgical interventions. Its unique characteristics and composition provide the dual action of:
1. immediate bulking effect by the gel carrier
2. sustained performance by the polycaprolactone microspheres and related mechanism of action
Urolon™ can be administered non-surgically using a transurethral approach via cystoscopy. Urolon™ offers the following performance properties:
- Immediate bulking effect
- Sustained performance
- Lower associated-risks when compared to surgery2
Immediate bulking effect
Most noticeable is the ability of Urolon™ to restore lost volume around the urethra by providing an immediate bulking effect due to the optimum visco-elastic gel carrier.
A sustained performance is achieved through the unique mode of action of Urolon™ and its bioresorption profile.